47 results
10-K
2023 FY
EX-4.11
GALT
Galectin Therapeutics Inc
Annual report
29 Mar 24
7:51am
10-K
2023 FY
EX-4.12
GALT
Galectin Therapeutics Inc
Annual report
29 Mar 24
7:51am
SC 13D/A
EX-4
10X Fund, L.P.
1 Dec 23
GALECTIN THERAPEUTICS / 10X Fund ownership change
4:38pm
8-K
EX-4.1
GALT
Galectin Therapeutics Inc
26 Jul 22
Galectin Therapeutics Announces $60 Million Credit Line
7:57am
10-K
2020 FY
EX-4.20
GALT
Galectin Therapeutics Inc
Annual report
31 Mar 21
7:51am
8-K
EX-4.2
o68n5w7mts t0w1
15 Jan 19
Board Chairman Richard Uihlein extends existing $10 million unsecured line of credit for two additional years
7:55am
8-K
EX-4.3
ek6nxyyc
15 Jan 19
Board Chairman Richard Uihlein extends existing $10 million unsecured line of credit for two additional years
7:55am
8-K
EX-4.1
zz0na7j1u2p3q7uoa
15 Jan 19
Board Chairman Richard Uihlein extends existing $10 million unsecured line of credit for two additional years
7:55am
8-K/A
EX-4.1
b154k7 tra
3 Jan 19
Entry into a Material Definitive Agreement
8:30am
8-K
EX-4.1
13g9og5 3d97wzhw
19 Dec 17
Galectin Therapeutics Announces $10 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Into 2019
12:00am
8-K
EX-4.1
d2fho2dl5g1apx 78q
29 Dec 16
Galectin Therapeutics Announces $4 Million In New Equity Financings
12:00am
8-K
EX-4.2
vrb2eewq6
27 Sep 16
Galectin Therapeutics Announces Top-Line Data from Exploratory Phase 2a Pilot Trial (NASH-FX) with GR-MD-02 in NASH Patients with Advanced Fibrosis
12:00am
8-K
EX-4.1
d142lx540y cnk4
27 Sep 16
Galectin Therapeutics Announces Top-Line Data from Exploratory Phase 2a Pilot Trial (NASH-FX) with GR-MD-02 in NASH Patients with Advanced Fibrosis
12:00am
8-K
EX-4.1
2i3 xeyfyx9ap0
20 Nov 15
Galectin Therapeutics Announces Pricing of $9.8 Million
12:00am